EDP Sciences logo
Subscriber Authentication Point
Rechercher
Menu
Accueil Tous les numéros Volume 42 / Numéro 5 (Mai 2026) Med Sci (Paris), 42 5 (2026) 451-458 References
Open Access
Issue
Med Sci (Paris)
Volume 42, Number 5, Mai 2026
Page(s) 451 - 458
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2026080
Published online 29 mai 2026
  1. Herberman RB, Nunn ME, Holden HT, et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975 ; 16 : 230–9. [Google Scholar]
  2. Kiessling R, Klein E, Pross H, et al. Natural killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975 ; 5 : 117–21. [Google Scholar]
  3. Kiessling R, Klein E, Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975 ; 5 : 112–7. [Google Scholar]
  4. Melsen JE, Themeli M, Ostaijen-Ten Dam MM. Protocol for isolation, stimulation and functional profiling of primary and IPSC-derived human NK cells. Bio Protoc 2020 ; 10 : 3845. [Google Scholar]
  5. Vivier E, Artis D, Colonna M, et al. Innate lymphoid cells: 10 years on. Cell 2018 ; 174 : 1054–66. [Google Scholar]
  6. Lanier LL, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986 ; 136 : 4480–6. [Google Scholar]
  7. Juelke K, Killig M, Luetke-Eversloh M. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 2010 ; 116 : 1299–307. [Google Scholar]
  8. Lopez-Vergès S, Milush JM, Pandey S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010 ; 116 : 3865–74. [Google Scholar]
  9. Luetke-Eversloh M, Killig M, Romagnani C. Signatures of human NK cell development and terminal differentiation. Front Immunol 2013 ; 4 : 499. [Google Scholar]
  10. Yu J, Mao HC, Wei M. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 2010 ; 115 : 274–81. [Google Scholar]
  11. Bjorkstrom NK, Riese P, Heuts F. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010 ; 116 : 3853–64. [Google Scholar]
  12. Hammer Q, Ruckert T, Borst EM. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol 2018 ; 19 : 453–63. [Google Scholar]
  13. Guma M, Angulo A, Vilches C. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004 ; 104 : 3664–71. [Google Scholar]
  14. Ruckert T, Romagnani C. Extrinsic and intrinsic drivers of natural killer cell clonality. Immunol Rev 2024 ; 323 : 80–106. [Google Scholar]
  15. Narni-Mancinelli E, Ugolini S, Vivier E. Les cellules natural killer: adaptation et mémoire dans le système immunitaire inné. Med Sci (Paris) 2013 ; 29 : 389–95. [Google Scholar]
  16. Schlums H, Cichocki F, Tesi B. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015 ; 42 : 443–56. [Google Scholar]
  17. Sojka DK, Plougastel-Douglas B, Yang L, et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. Elife 2014 ; 3 : e01659. [Google Scholar]
  18. Bjorkstrom NK, Ljunggren HG, Michaelsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol 2016 ; 16 : 310–20. [Google Scholar]
  19. Freud AG, Mundy-Bosse BL, Yu J, et al. The broad spectrum of human natural killer cell diversity. Immunity 2017 ; 47 : 820–33. [Google Scholar]
  20. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol 2017 ; 18 : 1004–15. [Google Scholar]
  21. Romagnani C, Juelke K, Falco M. CD56brightCD16-killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 2007 ; 178 : 4947–55. [Google Scholar]
  22. Chretien A-S, Devillier R, Granjeaud S, et al. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Proc Natl Acad Sci USA 2021 ; 118 : e2020459118. [Google Scholar]
  23. Horowitz A, Strauss-Albee DM, Leipold M. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med 2013 ; 5 : 208ra145. [Google Scholar]
  24. Coënon L, Geindreau M, Ghiringhelli F, et al. Natural killer cells at the frontline in the fight against cancer. Cell Death Dis 2024 ; 15 : 614. [Google Scholar]
  25. Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol 2017 ; 8 : 1124. [Google Scholar]
  26. Böttcher JP, Bonavita E, Chakravarty P, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 2018 ; 172 : 1022–1037.e14. [Google Scholar]
  27. Allen F, Bobanga ID, Rauhe P, et al. CCL3 augments tumor rejection and enhances CD8+T cell infiltration through NK and CD103+ dendritic cell recruitment via IFNγ. Oncoimmunology 2018 ; 7 : e1393598. [Google Scholar]
  28. Lopez-Soto A, Gonzalez S, Smyth MJ, et al. Control of metastasis by NK cells. Cancer Cell 2017 ; 32 : 135–54. [Google Scholar]
  29. Huergo-Zapico L, Acebes-Huerta A, Lopez-Soto A. Molecular bases for the regulation of NKG2D ligands in cancer. Front Immunol 2014 ; 5 : 106. [Google Scholar]
  30. Okumura G, Iguchi-Manaka A, Murata R, et al. Tumor-derived soluble CD155 inhibits DNAM-1–mediated antitumor activity of natural killer cells. J Exp Med 2020 ; 217 : e20191290. [Google Scholar]
  31. Merino AM, Kim H, Miller JS, et al. Unraveling exhaustion in adaptive and conventional NK cells. J Leukoc Biol 2020 ; 108 : 1361–8. [Google Scholar]
  32. Platonova S, Cherfils-Vicini J, Damotte D. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011 ; 71 : 5412–22. [Google Scholar]
  33. Sun C, Xu J, Huang Q. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology 2017 ; 6 : e1264562. [Google Scholar]
  34. Cornen S, Andre P, Gauthier L. Les cellules natural killer : des cibles prometteuses dans la thérapie contre le cancer. Med Sci (Paris 2019 ; 35 : 990–2. [Google Scholar]
  35. Vijayan D, Young A, Teng MWL, et al. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 2017 ; 17 : 709–24. [Google Scholar]
  36. Holt D, Ma X, Kundu N, et al. Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother 2011 ; 60 : 1577–86. [Google Scholar]
  37. Rautela J, Dagley LF, Oliveira CC. Therapeutic blockade of activin-A improves NK cell function and antitumor immunity. Sci Signal 2019 ; 12 : eaat7527. [Google Scholar]
  38. Ma S, Caligiuri MA, Yu J. Harnessing natural killer cells for lung cancer therapy. Cancer Res 2023 ; 83 : 3327–39. [Google Scholar]
  39. Trzonkowski P, Szmit E, Mysliwska J. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004 ; 112 : 258–67. [Google Scholar]
  40. Park MD, Reyes-Torres I, LeBerichel J. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat Immunol 2023 ; 24 : 792–801. [Google Scholar]
  41. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015 ; 15 : 486–99. [Google Scholar]
  42. Pouxvielh K, Marotel M, Drouillard A, et al. Tumor-induced natural killer cell dysfunction is a rapid and reversible process uncoupled from the expression of immune checkpoints. Sci Adv 2024 ; 10 : eadn0164. [Google Scholar]
  43. Rebuffet L, Melsen JE, Escalière B, et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat Immunol 2024 ; 25 : 1474–88. [Google Scholar]
  44. Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell 2021 ; 184 : 3573–3587.e29. [Google Scholar]
  45. Ding Y, Lavaert M, Grassmann S, et al. Distinct developmental pathways generate functionally distinct populations of natural killer cells. Nat Immunol 2024 ; 25 : 1183–92. [Google Scholar]
  46. Tang F, Li J, Qi L, et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 2023 ; 186 : 4235–4251.e20. [Google Scholar]
  47. Netskar H, Pfefferle A, Goodridge JP, et al. Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping. Nat Immunol 2024 ; 25 : 1445–59. [Google Scholar]
  48. Serger C, Rebuffet L, Sandholzer MT, et al. Integrated single cell analysis identifies CD39+ tumor-associated NK cells with cytotoxic potential in lung cancer. 2025. [Google Scholar]
  49. Duhen T, Duhen R, Montler R. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun 2018 ; 9 : 2724. [Google Scholar]
  50. Cayatte M, Picant V, Vétizou M, et al. Bringing natural killer cells to the clinic: Opportunities beyond cancer. J Exp Med 2026 ; 223 : e20250612. [Google Scholar]
  51. Bernard PL, Laletin V, Pastor S, et al. Une piste en immunothérapie du cancer : cibler la signalisation des cellules NK. Med Sci (Paris) 2020 ; 36 : 50–5. [Google Scholar]
  52. Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med 2016 ; 8 : 357ra123. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.